Feasibility of engineered Bacillus subtilis for use as a microbiome-based topical drug delivery platform.

ABSTRACT: Non-adherence to medication is a major challenge in healthcare that results in worsened treatment outcomes for patients. Reducing the frequency of required administrations could improve adherence but is challenging for topical drug delivery due to the generally short residence time of topical formulations on the skin. In this study, we sought to determine the feasibility of developing a microbiome-based, long-acting, topical delivery platform using Bacillus subtilis for drug production and delivery on the skin, which was assessed using green fluorescent protein as a model heterologous protein for delivery. We developed a computational model of bacteria population dynamics on the skin and used its qualitative predictions to guide experimental design choices. Using an ex vivo p

SUBMITTER: Montgomery VA 

PROVIDER: S-EPMC11256169 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature